Press Releases

 
Press Releases
Date Title and Summary View
Dec 11, 2014 PORTLAND, Ore., Dec. 11, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that initial immunohistochemistry (IHC) screening data from the NeuVax&#...
Dec 8, 2014 Phase 1 results demonstrate GALE-401 reduces platelet counts with tolerable safety profilePreliminary Phase 2 clinical trial data show promising platelet response with top-line data to be presented mid-year 2015 PORTLAND, Ore., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and comm...
Dec 5, 2014 PORTLAND, Ore., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that initial immunohistochemistry (IHC) screening data from the NeuVax...
Dec 2, 2014 PORTLAND, Ore., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that it has received a Notice of Allowance from the United States Patent ...
Dec 1, 2014 PORTLAND, Ore., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's Phase 1 clinical trials of GALE-401, or Anag...
Nov 25, 2014 PORTLAND, Ore., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will...
Nov 20, 2014 Initial Purchase of $5.0 Million at $2.00 per share, 9% higher than the market close as of November 18, 2014Agreement structure provides Galena control and flexibility to access capital over the long-term to fund the Company's clinical and development programs PORTLAND, Ore., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. ("Galena" or...
Nov 18, 2014 Enrollment completed six months ahead of schedule Phase 1 and early Phase 2 data to be presented at the American Society of Hematology 56th Annual Meeting in December, with top-line data in mid-year 2015 PORTLAND, Ore., Nov. 18, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commer...
Nov 13, 2014 PORTLAND, Ore., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will...
Nov 11, 2014 Trial expands the eligible patient population and overall NeuVax clinical trial portfolio Recent patent allowance provides intellectual property protection for NeuVax in combination with Herceptin in any HER2/neu expressing cancer PORTLAND, Ore., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company...
Page:
1
... NextLast
= add release to Briefcase